FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Percy Ivy

Research Profile

Disorders

Neoplasms

Chemicals & Drugs

Concepts & Ideas

Procedures

Antineoplastic Combined Chemotherapy Protocols

Organizations

National Cancer Institute (U.S.)

Physiology

Geographic Areas

United States

Living Beings

Young Adult

Co-author Network

Publications

TOP 3
Amir Mortazavi; Gregory A Otterson; Mitch A Phelps; Lai Wei; Xin Wu; Yun Yen; Bing-Sen Zhou; Deidre Deam; Michael R Grever; Erica J Harper; William J Hicks; S Percy Ivy; Yonghua Ling; Xiyong Liu; Zhongfa Liu; Ludmila Katherine Martin; J Paul Monk; Tanios Bekaii-Saab
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Jason J Luke; Lawrence V Rubinstein; Gary L Smith; S Percy Ivy; Pamela J Harris
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Shivaani Kummar; Eva Majerova; Larry Rubinstein; Deborah Allen; Larry Anderson; James H Doroshow; Pamela Harris; Kimberly Hill; Yvonne Horneffer; S Percy Ivy; Jerry M Collins
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Percy Ivy (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Amir Mortazavi; Gregory A Otterson; Mitch A Phelps; Lai Wei; Xin Wu; Yun Yen; Bing-Sen Zhou; Deidre Deam; Michael R Grever; Erica J Harper; William J Hicks; S Percy Ivy; Yonghua Ling; Xiyong Liu; Zhongfa Liu; Ludmila Katherine Martin; J Paul Monk; Tanios Bekaii-Saab
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Investigational new drugs 2013;31(3):685-95.
2013: Jason J Luke; Lawrence V Rubinstein; Gary L Smith; S Percy Ivy; Pamela J Harris
Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
Melanoma research 2013;23(2):152-8.
2013: Shivaani Kummar; Eva Majerova; Larry Rubinstein; Deborah Allen; Larry Anderson; James H Doroshow; Pamela Harris; Kimberly Hill; Yvonne Horneffer; S Percy Ivy; Jerry M Collins
First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(7):1852-7.
2013: Margaret E Macy; Aru Narendren; Katherine Rolla; Tanya Trippett; James Whitlock; Robert J Arceci; Rochelle Bagatell; Jessica Boklan; Uwe Christians; Tracey Duncan; Lia Gore; Cynthia Herzog; Stephen P Hunger; S Percy Ivy
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.
Pediatric blood & cancer 2013;60(2):230-6.
2012: Gopa Iyer; Steven M Larson; Michael J Morris; Dana Elizabeth Rathkopf; Neal Rosen; Howard I Scher; Lawrence H Schwartz; Susan F Slovin; Tracy Curley; Anthony Delacruz; Merrill J Egorin; Glenn Heller; S Percy Ivy; Macaulay Steers; Qing Ye; David B Solit
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Cancer chemotherapy and pharmacology 2012;69(4):1089-97.
2012: Richard M Steingart; George L Bakris; Helen X Chen; Ming-Hui Chen; Thomas Force; S Percy Ivy; Carl V Leier; Daniel Lenihan; JoAnn Lindenfeld; Glenn Liu; Michael L Maitland; Scot C Remick; W H Wilson Tang
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
American heart journal 2012;163(2):156-63.
2012: Andrea E Wahner Hendrickson; John K Camoriano; Gerardo Colon-Otero; Charles Erlichman; Gretchen Glaser; S Percy Ivy; Larry M Karnitz; Scott H Kaufmann; Ann L Oberg; Prema P Peethambaram; Paul Haluska
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Gynecologic oncology 2012;124(2):210-5.
2011: Ticiana B Leal; Heinz-Josef Lenz; Patricia M LoRusso; Sridhar Mani; James Mier; Angela Davies; Merrill J Egorin; Anne Hamilton; S Percy Ivy; Rachel Neuwirth; Ramesh K Ramanathan; Scot C Remick; John Sarantopoulos; Stephen Shibata; Chris H Takimoto; Karthik Venkatakrishnan; Lisa von Moltke; John J Wright; Daniel Mulkerin
Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
Cancer chemotherapy and pharmacology 2011;68(6):1439-47.
2011: Scott H Kaufmann; Mark R Litzow; David A Loegering; Matthew J Maurer; Ruben A Mesa; Kevin L Peterson; Joel M Reid; Paula A Schneider; B Douglas Smith; David P Steensma; Alex A. Adjei; Matthew M Ames; Yuhong Chen; Charles Erlichman; Karen S Flatten; Jacqueline Greer; William Hogan; S Percy Ivy; Judith E Karp; Larry M Karnitz
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
Haematologica 2011;96(11):1619-26.
2011: Joleen Hubbard; Charles Erlichman; David O Toft; Rui Qin; Bridget Stensgard; Sara Felten; Cynthia Ten Eyck; Gretchen Batzel; S Percy Ivy; Paul Haluska
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
Investigational new drugs 2011;29(3):473-80.
2011: Naoko Takebe; Pamela J Harris; Ronald Q Warren; S Percy Ivy
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.
Nature reviews. Clinical oncology 2011;8(2):97-106.
2011: Naoko Takebe; Ronald Q Warren; S Percy Ivy
Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition.
Breast cancer research : BCR 2011;13(3):211.
2010: Suresh S Ramalingam; Shivaani Kummar; John Sarantopoulos; Stephen Shibata; Patricia M LoRusso; Mara Yerk; Julianne Holleran; Yan Lin; Jan H Beumer; R Donald Harvey; S Percy Ivy; Chandra P Belani; Merrill J Egorin
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(29):4507-12.
2010: Pamela Jo Harris; Naoko Takebe; S Percy Ivy
Molecular conversations and the development of the hair follicle and basal cell carcinoma.
Cancer prevention research (Philadelphia, Pa.) 2010;3(10):1217-21.
2010: Keith C Bible; Vera J Suman; Julian R Molina; Robert C Smallridge; William J Maples; Michael E Menefee; Joseph Rubin; Kostandinos Sideras; John C Morris; Bryan McIver; Jill K Burton; Kevin P Webster; Carolyn Bieber; Anne M Traynor; Patrick J Flynn; Boon Cher Goh; Hui Tang; S Percy Ivy; Charles Erlichman
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
The lancet oncology 2010;11(10):962-72.
2010: Brian S Choi; Dona Alberti; William R Schelman; Jill M Kolesar; James P Thomas; Rebecca Marnocha; Jens Eickhoff; S Percy Ivy; George Wilding; Kyle D Holen
The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors.
Cancer chemotherapy and pharmacology 2010;66(5):973-80.
2010: Orren Beaty; Stacey Berg; Susan M Blaney; Marcio Malogolowkin; Mark Krailo; Ronald Knight; Paula Schaiquevich; Clinton Stewart; Zhengjia Chen; Marvin Nelson; Stephan Voss; S Percy Ivy; Peter Charles Adamson
A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study.
Pediatric blood & cancer 2010;55(3):440-5.
2010: Suresh S Ramalingam; Chandra P Belani; Philip C Mack; Everett E Vokes; Jeffrey Longmate; Ramaswamy Govindan; Marianna Koczywas; S Percy Ivy; David R Gandara
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010;5(8):1279-84.
2010: Kostandinos Sideras; Michael E Menefee; Jill K Burton; Charles Erlichman; Keith C Bible; S Percy Ivy
Profound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(19):e312-3.
2010: Naoko Takebe; S Percy Ivy
Controversies in cancer stem cells: targeting embryonic signaling pathways.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(12):3106-12.
2010: Michael L Maitland; George L Bakris; Henry R Black; Helen X Chen; Jean-Bernard Durand; William J Elliott; S Percy Ivy; Carl V Leier; Joann Lindenfeld; Glenn Liu; Scot C Remick; Richard M Steingart; W H Wilson Tang
Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Journal of the National Cancer Institute 2010;102(9):596-604.
2010: Ramesh K Ramanathan; Merrill J Egorin; Charles Erlichman; Scot C Remick; Suresh S Ramalingam; Cynthia Naret; Julianne L Holleran; Cynthia J Teneyck; S Percy Ivy; Chandra P Belani
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(9):1520-6.
2010: Lesley Seymour; S Percy Ivy; Daniel Sargent; David Spriggs; Laurence H Baker; Larry Rubinstein; Mark J Ratain; Michael Le Blanc; David Stewart; John Crowley; Susan Groshen; Jeff Humphrey; Pamela West; Donald Berry
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(6):1764-9.
2010: S Percy Ivy; Lillian L Siu; Elizabeth Garrett-Mayer; Larry Rubinstein
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(6):1726-36.
2010: Shivaani Kummar; Martin E Gutierrez; Erin R Gardner; Xiaohong Chen; William D Figg; Maria Zajac-Kaye; Min Chen; Seth M Steinberg; Christine A Muir; Mary Ann Yancey; Yvonne R Horneffer; Lamin Juwara; Giovanni Melillo; S Percy Ivy; Maria Merino; Len Neckers; Patricia S Steeg; BA Conley; Giuseppe Giaccone; James Doroshow; Anthony J Murgo
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
European journal of cancer (Oxford, England : 1990) 2010;46(2):340-7.
2009: S Percy Ivy; Jeannette Y Wick; Bennett M Kaufman
An overview of small-molecule inhibitors of VEGFR signaling.
Nature reviews. Clinical oncology 2009;6(10):569-79.
2009: Joanna M Brell; Smitha S Krishnamurthi; Milind Javle; Joel Saltzman; Ira Wollner; Robert Pelley; Afshin Dowlati; Belagodu N Kantharaj; Mark D Schluchter; Linda Rath; S Percy Ivy; Scot C Remick
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Cancer chemotherapy and pharmacology 2009;63(5):851-7.
2009: Elisabeth Iljas Heath; Patricia M LoRusso; S Percy Ivy; Larry Rubinstein; Michaele C Christian; Lance K Heilbrun
Theoretical and practical application of traditional and accelerated titration Phase I clinical trial designs: the Wayne State University experience.
Journal of biopharmaceutical statistics 2009;19(3):414-23.
2008: Elisabeth Iljas Heath; David W Hillman; Ulka Nitin Vaishampayan; Shijie Sheng; Asfar S Azmi; Felicity WK Harper; Melvin Gaskins; Henry C Pitot; Winston Tan; S Percy Ivy; Roberto Pili; Michael A Carducci; Charles Erlichman; Glenn Liu
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7940-6.
2008: Sakkaraiappan Ramalingam; Merrill J Egorin; Ramesh K Ramanathan; Scot C Remick; Rachel Sikorski; Theodore F Lagattuta; Gurkamal S Chatta; David M Friedland; Ronald G Stoller; Douglas M Potter; S Percy Ivy; Chandra P Belani
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3456-61.
2008: Joseph Gibbons; Merrill J Egorin; Ramesh K Ramanathan; Pingfu Fu; Daniel Mulkerin; Stephen Shibata; Chris H Takimoto; Sridhar Mani; Patricia M LoRusso; Jean L Grem; Anna Pavlick; Heinz-Josef Lenz; Susan M Flick; Sherrie Reynolds; Theodore F Lagattuta; Robert A Parise; Yanfeng Wang; Anthony J Murgo; S Percy Ivy; Scot C Remick
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):570-6.
2008: Ramesh K Ramanathan; Merrill J Egorin; Chris H Takimoto; Scot C Remick; James Doroshow; Patricia M LoRusso; Daniel Mulkerin; Jean L Grem; Anne Hamilton; Anthony J Murgo; Douglas M Potter; Chandra P Belani; Michael J Hayes; Bin Peng; S Percy Ivy
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):563-9.
2007: Julie L Eiseman; Jianxia Guo; Ramesh K Ramanathan; Chandra P Belani; David B Solit; Howard I Scher; S Percy Ivy; Eleanor G Zuhowski; Merrill J Egorin
Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2121-7.
2007: Brenda J Weigel; Susan M Blaney; Joel M Reid; Stephanie L Safgren; Rochelle Bagatell; John H Kersey; Joseph P Neglia; S Percy Ivy; Ashish Ingle; Luke Whitesell; Richard J Gilbertson; Mark Krailo; Matthew Ames; Peter Charles Adamson
A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1789-93.
2007: Rochelle Bagatell; Lia Gore; Merrill J Egorin; Richard Ho; Glenn Heller; Nichole Boucher; Eleanor G Zuhowski; James A Whitlock; Stephen P Hunger; Aru Narendran; Howard M Katzenstein; Robert J Arceci; Jessica Boklan; Cynthia E Herzog; Luke Whitesell; S Percy Ivy; Tanya M Trippett
Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1783-8.
2007: David B Solit; S Percy Ivy; Catherine Kopil; Rachel Sikorski; Michael J Morris; Susan F Slovin; W Kevin Kelly; Anthony Delacruz; Tracy Curley; Glenn Heller; Steven M Larson; Lawrence H Schwartz; Merrill J Egorin; Neal Rosen; Howard I Scher
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1775-82.
2007: Ramesh K Ramanathan; Merrill J Egorin; Julie L Eiseman; Sakkaraiappan Ramalingam; David M Friedland; Sanjiv S Agarwala; S Percy Ivy; Douglas M Potter; Gurkamal S Chatta; Eleanor G Zuhowski; Ronald G Stoller; Cynthia Naret; Jianxia Guo; Chandra P Belani
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1769-74.
2006: Ramesh K Ramanathan; Marwan G Fakih; Sridhar Mani; Melvin Deutsch; Raymond P Perez; Mark A Ritter; Julie L Eiseman; S Percy Ivy; Donald L Trump; Chandra P Belani; Robert A Parise; Douglas M Potter; Merrill J Egorin
Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers.
Cancer chemotherapy and pharmacology 2006;57(4):465-74.
2005: Lawrence V Rubinstein; Edward L Korn; Boris Freidlin; Sally Hunsberger; S Percy Ivy; Malcolm A Smith
Design issues of randomized phase II trials and a proposal for phase II screening trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(28):7199-206.
2005: Lawrence W Anderson; Jerry M Collins; Raymond W Klecker; Aspandiar G Katki; Ralph E Parchment; Ramesh R Boinpally; Patricia M LoRusso; S Percy Ivy
Metabolic profile of XK469 (2(R)-[4-(7-chloro-2-quinoxalinyl)oxyphenoxy]-propionic acid; NSC698215) in patients and in vitro: low potential for active or toxic metabolites or for drug-drug interactions.
Cancer chemotherapy and pharmacology 2005;56(4):351-7.
2005: Douglas P Olson; Barbara J Taylor; Mei K La; Harland Sather; Gregory H Reaman; S Percy Ivy
The prognostic significance of P-glycoprotein, multidrug resistance-related protein 1 and lung resistance protein in pediatric acute lymphoblastic leukemia: a retrospective study of 295 newly diagnosed patients by the Children's Oncology Group.
Leukemia & lymphoma 2005;46(5):681-91.
2005: Ramesh K Ramanathan; Donald L Trump; Julie L Eiseman; Chandra P Belani; Sanjiv S Agarwala; Eleanor G Zuhowski; Jing Lan; Douglas M Potter; S Percy Ivy; Sakkaraiappan Ramalingam; Adam Brufsky; Michael K K Wong; Susan Tutchko; Merrill J Egorin
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3385-91.
2004: Bennett Kaufman; Orit Scharf; Jeffrey Arbeit; Margaret Ashcroft; J Martin Brown; Richard K Bruick; J Donald Chapman; Sydney M Evans; Amato J Giaccia; Adrian L Harris; Eric Huang; Randall Johnson; William Kaelin; Cameron J Koch; Patrick Maxwell; James Mitchell; Len Neckers; Garth Powis; Joseph Rajendran; Gregg L Semenza; Jonathan Simons; Erik Storkebaum; Michael J Welch; Murray Whitelaw; Giovanni Melillo; S Percy Ivy
Proceedings of the Oxygen Homeostasis/Hypoxia Meeting.
Cancer research 2004;64(9):3350-6.
2003: Len Neckers; S Percy Ivy
Heat shock protein 90.
Current opinion in oncology 2003;15(6):419-24.
2001: Barbara J Taylor; Douglas P Olson; S Percy Ivy
Detection of P-glycoprotein in cell lines and leukemic blasts: failure of select monoclonal antibodies to detect clinically significant Pgp levels in primary cells.
Leukemia research 2001;25(12):1127-35.
2001: Douglas P Olson; Barbara J Taylor; S Percy Ivy
Detection of MRP functional activity: calcein AM but not BCECF AM as a Multidrug Resistance-related Protein (MRP1) substrate.
Cytometry 2001;46(2):105-13.
2000: S Percy Ivy
NCI cooperative research and development agreements.
Oncology (Williston Park, N.Y.) 2000;14(12 Suppl 11):27-9.
1999: S Percy Ivy; G Blatner; Bruce D Cheson
Clinical trials referral resource. Clinical trials of combination regimens containing oxaliplatin.
Oncology (Williston Park, N.Y.) 1999;13(8):1116-8.
1999: S Percy Ivy; G Blatner; Bruce D Cheson
Clinical trials referral resource. Clinical trials of single-agent oxaliplatin.
Oncology (Williston Park, N.Y.) 1999;13(7):966, 969-70.
1999: S Percy Ivy; G Blatner; Bruce D Cheson
Clinical trials referral resource. Clinical trials with gadolinium-texaphyrin and lutetium-texaphyrin.
Oncology (Williston Park, N.Y.) 1999;13(5):671, 674-6.
1997: M Gong; J Yess; T Connolly; S Percy Ivy; T Ohnuma; Kenneth H Cowan; Jeffrey A Moscow
Molecular mechanism of antifolate transport-deficiency in a methotrexate-resistant MOLT-3 human leukemia cell line.
Blood 1997;89(7):2494-9.
1997: Jeffrey A Moscow; E Schneider; S Percy Ivy; Kenneth H Cowan
Multidrug resistance.
Cancer chemotherapy and biological response modifiers 1997;17():139-77.
1988: S Percy Ivy; A Tulpule; C R Fairchild; S D Averbuch; Charles E Myers; Daniel W Nebert; W M Baird; Kenneth H Cowan
Altered regulation of P-450IA1 expression in a multidrug-resistant MCF-7 human breast cancer cell line.
The Journal of biological chemistry 1988;263(35):19119-25.
1987: C R Fairchild; S Percy Ivy; T Rushmore; G Lee; P Koo; M E Goldsmith; Charles E Myers; E Farber; Kenneth H Cowan
Carcinogen-induced mdr overexpression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(21):7701-5.
1987: C R Fairchild; S Percy Ivy; C S Kao-Shan; J Whang-Peng; N Rosen; Mark Israel; Peter W Melera; Kenneth H Cowan; M E Goldsmith
Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells.
Cancer research 1987;47(19):5141-8.